Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "of Oncology"


8 mentions found


Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed for a targeted destructive effect and spare healthy cells. The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. The drugmaker expects more than $10 billion in sales from Seagen products in 2030, and another $15 billion from its other recent acquisitions. Pfizer said antitrust regulators could closely review the deal due to its size but eventually approve it. Pfizer rival Merck & Co Inc (MRK.N) and Seagen were in advanced deal talks last year but those reportedly collapsed over antitrust concerns.
Healthcare companies are launching programs left and right to prescribe trendy weight-loss drugs. And Ro, a startup that prescribes and sells products like Viagra and hair-loss pills to consumers, is going all in with a program it launched in January to prescribe the weight-loss drugs to patients online. Even startups like Noom, which quietly started a program prescribing GLP-1 medications, could stand to benefit from the drugs' popularity after a tumultuous year for the startup. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. But for some companies, stepping into prescribing these new weight-loss medications seems to simply be the natural next step for growth.
Pfizer signs $43 bln Seagen deal in cancer drug push
  + stars: | 2023-03-13 | by ( Manas Mishra | ) www.reuters.com   time to read: +2 min
The deal, Pfizer's biggest in a string of acquisitions after a once-in-a-lifetime cash windfall from its COVID-19 vaccine and pill, will add four approved cancer therapies with combined sales of nearly $2 billion in 2022. Pfizer will pay $229 in cash per Seagen share, a 32.7% premium to Friday's closing price. The drugmaker expects more than $10 billion in "risk-adjusted" sales from Seagen in 2030. Pfizer's portfolio of oncology therapies includes 24 approved drugs, including breast cancer treatment Ibrance. Pfizer rival Merck & Co Inc (MRK.N) and Seagen were in advanced deal talks last year but that reportedly collapsed over fears of tough antitrust scrutiny.
The gene-editing startup Aera has hired biotech vets Akin Akinc as CEO and John Maraganore as chairman. CRISPR pioneer Feng Zhang's newest gene-editing venture has attracted two longtime leaders of the biotech giant Alnylam Pharmaceuticals, Insider has learned. Former Alnylam CEO John Maraganore is chairman of Aera. The SEND technology could allow gene-editing technology to treat more diseases. Based on Zhang's SEND research, Aera hopes to deliver gene-editing tools to more organs, ultimately expanding the number of diseases CRISPR can impact.
We are lowering our relative ratings on ALLY, COF and MTB from Overweight to Equal Weight and ZION from Equal Weight to Underweight." Wells Fargo upgrades Wynn to overweight from equal weight Wells said in its upgrade of the casino company that it sees a significant reopening opportunity for the stock. " Wells Fargo initiates Mondelez as overweight Wells said the food products company has "superior" fundamentals. Wells Fargo downgrades Molson Coors to equal weight from overweight Wells said in its downgrade of the stock that it sees downside to estimates. Baird names Wells Fargo a top 2023 pick Baird said it likes the risk/reward for the banking giant in 2023.
AstraZeneca boosts cancer portfolio with $320 mln Neogene deal
  + stars: | 2022-11-29 | by ( ) www.reuters.com   time to read: +2 min
Nov 29 (Reuters) - AstraZeneca (AZN.L) will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis (NOVN.S) and Gilead (GILD.O). Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain proteins on the surface of cancer cells. Linnemann founded Neogene in the Netherlands in 2018 along with the Netherlands Cancer Institute's Ton Schumacher. AstraZeneca will make an initial payment of $200 million to Neogene, with a further $120 million dependent on the company meeting certain targets.
Social media users are sharing claims that rubbing hydrogen peroxide onto the skin can treat cancer and that oxygen can kill cancer cells. “Neither hydrogen peroxide nor oxygen has undergone the rigorous scrutiny and testing needed to prove that these therapies can treat cancer or kill cancer cells,” Tyler Johnson, a clinical assistant professor of oncology at Stanford Medicine, said via email. While application of hydrogen peroxide can reach the bloodstream, he explained, it will not reach to a tumor far enough to have any helpful effect – in fact, "large amounts of ingested hydrogen peroxide are known to be toxic and cause internal burns." “The most highly touted ‘hyperoxygenating’ agents are hydrogen peroxide, germanium sesquioxide, and ozone,” the review explains. There is no evidence that rubbing hydrogen peroxide on the skin, consuming it, or using other unproven methods to increase oxygen in the body will have an effect on cancer cells.
With a successor search underway, Werner Baumann is entering his last chapter as Bayer's CEO. Baumann told Insider he's more excited today about Bayer's future than several years ago. The exec wants Bayer to become a top 10 cancer player by 2030, and recently opened a Cambridge lab. CAMBRIDGE, Massachusetts — Within his first month as CEO of the German giant Bayer, Werner Baumann took a big, legacy-making swing. Baumann says Bayer's future is in oncologyWerner Baumann, right, CEO of Bayer, and Werner Wenning, chairman of the Supervisory Board of Bayer.
Total: 8